Investor Presentation Q1 2023
29
Investor presentation
First three months of 2023
Novo NordiskⓇ
Pipeline supports significant growth opportunities across all four
strategic focus areas
PHASE 1
NN1845 - GSI
NN1471 - Pumpinsulin
NN9041 - DNA Immunotherapy
NN9541 - Oral GLP-1/GIP co-agonist
NN9917 - SemaDapa FDC
NN9904-Once weekly oral sema
NN9487 - Oral Amycretin
NN6020 DCR-AUD¹
NN6582LXR(a) in NASH
NN6581 - MARC1 in NASH
NN9003 - Stem Cells in HF
NN9001 - Stem Cells in PD
PHASE 2
NN9388-Cagrisema
NN9775
PYY 1875 analogue
NN7533 Ndec in SCD
PHASE 3
NN1535 Icosema
NN9924 Oral Semaglutide 25 and 50 mg
NN9536-Semaglutide 7.2 mg
NN7535 - Etavopivat in Beta thalassemia NN9838 - Cagrisema
NN9931 Gilead in NASH
-
NN9500 FGF-21 in NASH
NN6021 - Belcesiran in AATLD
NN6019-ATTR Cardiomypathy
NN9932 - Oral Semaglutide 50 mg obesity²
NN9931 Semaglutide 2.4 mg in NASH
NN6535 Semaglutide 14.0 mg in AD
NN6018 Ziltivekimab in ASCVD
NN7769 Mim8 in HA
NN7535 Etavopivat in SCD
Other PHASE 3 trials
_
SOUL Oral semaglutide 14.0
mg CVOT
FOCUS Semaglutide 1.0 mg in diabetic retinopathy
FLOW Semaglutide 1.0 mg in CKD
STRIDE-Semaglutide 1.0 mg in PAD
STEP Semaglutide 2.4 mg in HFPEF
SELECT Semaglutide 2.4 mg in obese population
SUBMITTED
NN1436 - Insulin Icodec
NN8640 Sogroya®
NN7415
Concizumab³ in HwI
NN7022 Nedosiran in PH
-
APPROVED
Tresiba
XultophyⓇ
LevemirⓇ
RyzodegⓇ
NovoMixⓇ
FiaspⓇ
NovoRapidⓇ
RybelsusⓇ
OzempicⓇ4
VictozaⓇ
WegovyⓇ
SaxendaⓇ
NovoSevenⓇ
Novo Eight®
EsperoctⓇ
NovoThirteenⓇ
Refixia®
Diabetes care
Obesity care
Rare blood disorders
Rare endocrine disorders
Other serious chronic diseases
NorditropinⓇ
SogroyaⓇs
1 Dicerna-Alcohol Use Disorder; 225 mg trial also initiated; 3 Submitted to EU/JP for HwI; 4 Higher doses of injectable semaglutide (8 mg and 16 mg) tested in phase 2; 5 Approved in the EU, the US and Japan for adult growth hormone disorder, approved in the US
for paediatric growth hormone disorder; AD: Alzheimer's Disease; ASCVD: Atherosclerotic Cardiovascular Disease; CKD: chronic kidney disease; CVOT: Cardiovascular outcome trial; FDC: Fixed-dose combination; FGF-21: Fibroblast growth factor 21; GDF15:
Growth differentiation factor 15; GHD: Growth hormone disorder; GSI: Glucose Sensitive Insulin; HA: Haemophilia A; HF: Heart failure; HFPEF: heart failure with preserved ejection fraction; HwI: Haemophilia with inhibitors; JP: Japan; MDS: myelodysplastic
syndrome; mAb: monocolonal antibody; NASH: Nonalcoholic Steatohepatitis; PYY: Peptide YY; PAD: Peripheral arterial disease; PD: Parkinson's Disease; PH: Primary hyperoxalate; QW: Once-weekly; SCD: Sickle cell disease; Sema: Semaglutide; US: United States.View entire presentation